Assess whether pediatric studies are necessary or waivable from draft

Situation

In an RWE group proposing a post-marketing study instead of a new RCT, draft labeling vs. the clinical study report is the evidence after a CMO 483 that maps to the NDA CMC module. Clinical-development physician has to pick Pediatric studies are necessary or Waivable for this Pharma & Life Sciences CMC and Development Pathways close using draft labeling vs. the clinical study report.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Pediatric studies are necessary / Waivable using draft labeling vs. the clinical study report after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• Authorize Pediatric studies are necessary now; draft labeling vs. the clinical study report already has the discriminator after a CMO 483 that maps to the NDA CMC module.
• Keep Waivable in force until draft labeling vs. the clinical study report is completed after a CMO 483 that maps to the NDA CMC module for clinical-development physician.
• Treat draft labeling vs. the clinical study report as Pediatric studies are necessary because both readings appear after a CMO 483 that maps to the NDA CMC module.
• Refuse a Pharma & Life Sciences close: clinical-development physician does not have the page pediatric studies are necessary turns on in draft labeling vs. the clinical study report.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether draft labeling vs. the clinical study report supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences CMC and Development Pathways file, read draft labeling vs. the clinical study report against a CMO 483 that maps to the NDA CMC module and write the one fact that would move pediatric studies are necessary for clinical-development physician.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / CMC and Development Pathways packet (draft labeling vs. the clinical study report after a CMO 483 that maps to the NDA CMC module). The follow-on CMC and Development Pathways action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.